RE002 T Cell Injection for the Treatment of KRAS G12D Mutated Solid Tumors

Trial Title: RE002 T Cell Injection for the Treatment of KRAS G12D Mutated Solid Tumors

NCT ID: NCT06546150

Condition: KRAS G12D
T Cell Therapy

Study type: Interventional

Study phase: Phase 1

Overall status: Not yet recruiting

Study design:

Allocation: N/A

Intervention model: Single Group Assignment

Primary purpose: Treatment

Masking: None (Open Label)

Intervention:

Intervention type: Biological
Intervention name: RE002 T cell
Description: All subjects who met the entry and exit criteria and signed the informed consent form were observed in hospital at the beginning of lymphocyte clearance chemotherapy, with the dosage of cyclophosphamide (600-800mg/m2/days,-5,-4 days) and fludarabine (25-30mg/m2/days,-5,-4,-3 days), at least two days after the completion of lymphocyte clearance chemotherapy.
Arm group label: RE002 T cell adoptive immunotherapy

Summary: At present, there is an urgent need for new drugs for KRAS mutant tumors in clinic. Preclinical studies support the specificity, safety and anti-tumor activity of RE002. Previous similar studies suggest the feasibility of TCR-T treatment, and measures have been taken to ensure the safe administration of RE002 and the close monitoring and management of adverse events. To sum up, RE002 has controllable safety and anti-tumor activity on KRAS mutant solid tumor, which can be preliminarily studied to provide support for clinical research of patients with advanced solid tumor.

Detailed description: This study is a single-center, open, single-arm, dose-increasing, single-dose phase I clinical trial of safety and tolerance. It is planned to recruit 30 patients with advanced malignant solid tumor with KRASG12D mutation. In this experiment, 3+3 dose increasing design was adopted, and the dose increasing scheme was as follows (deviation 30%): low dose group: 4×109, middle dose group: 8×109, and high dose group: 1.6×1010. At least 21 days before T cell infusion, PBMC (about 1×109) of the subjects were collected by a single blood cell separator. After gene editing, these cells were amplified in vitro and infused into the subjects after reaching the target number. The evaluation period of dose-limited toxicity (DLT) was 28 days after the first administration of each dose group. The subjects were administered at intervals, and the interval of administration began from the day of TCR-T cell infusion of the previous subject to the day of TCR-T cell infusion of the next subject. The interval between the first three subjects in the same dose group and the next subject (the same group or different groups) is at least 14 days; If one third of the subjects in the dose group have DLT, and three new subjects need to be added, the interval with the next subject (same group or different group) should be at least 21 days. All the subjects who met the entry and exit criteria and signed the informed consent form were observed in hospital at the beginning of lymphocyte clearance chemotherapy, with the dosage of cyclophosphamide (600-800mg/ m2/days,-5,-4 days) and fludarabine (25-30mg/m2/days,-5,-4,-3 days), at least two days after the completion of lymphocyte clearance chemotherapy. During the trial, the subjects can withdraw from the study at any time for any reason, which will not affect the subsequent treatment and care of the subjects by medical staff or medical institutions.

Criteria for eligibility:
Criteria:
Inclusion Criteria: 1. Subjects voluntarily participate in the study and sign informed consent; 2. Age ≥18 years old and ≤75 years old; 3. Advanced malignant solid tumors with clear pathological diagnosis; 4. Standard therapies failed or cannot be tolerated or lacks effective treatments; 5. Have at least one measurable lesion; 6. During the trial screening period, the following two indicators must be met (the sponsor is responsible): HLA-A* 11:01 positive; Tumor gene testing carries KRAS G12V mutation; 7. ECOG score 0-1 and expected survival time greater than 6 months; 8. Cardiac color ultrasound shows left ventricular ejection fraction ≥50%; 9. Laboratory examination results should meet the following specified indicators: White blood cell count ≧ 3.0×109/L; 1. Absolute neutrophil count ≧ 1.5×109/L (without G-CSF and GM-CSF support, enter at least 14 days before group); 2. Absolute lymphocyte count ≧ 0.5×109/L; 3. Platelets (PLT) ≧ 75×109/L (no blood transfusion treatment in the first 14 days); 4. Hemoglobin ≧ 100g/L (no blood transfusion treatment in the first 14 days); 5. Prothrombin time international normalized ratio INR ≦ 1.5×upper limit of normal time, unless anticoagulant therapy was received; 6. Partial prothrombin time (APTT) ≦ 1.5×upper limit of normal time, unless receiving antibiotics coagulation therapy; 7. Serum creatinine ≦ 1.5mg/dL (or 132.6μmol/L); 8. Aspartate aminotransferase (AST/SGOT) ≦ 2.5×ULN; 9. Alanine aminotransferase (ALT/SGPT) ≦ 2.5×ULN; 10. Total bilirubin (TBIL) ≦ 1.5×ULN; 11. In patients with liver metastasis, aspartate aminotransferase and alanine aminotransferase need to be ≦ 5×ULN. 10. Women of childbearing age who have not undergone sterilization before menopause must agree to use effective contraception within at least 12 months from the beginning of the study to T cell infusion, and the serum pregnancy test is negative within 14 days before the first treatment; 11. Men who have not undergone sterilization must agree to use effective contraception from the beginning of the study to at least 12 months after T cell infusion; 12. During the entire trial period, you can regularly visit the participating research institutions for relevant testing, evaluation and management. Exclusion Criteria: 1. Those who have received major surgery, conventional chemotherapy, large-area radiotherapy, immunotherapy or biological therapy anti-tumor treatment within 4 weeks before entering the trial; 2. Previous use of drugs targeting KRAS G12V mutations, including previous participation in cell therapy with similar targets Cellular testing and small molecule inhibitors targeting KRAS G12V mutations, etc.; 3. Allergic reactions are known to occur to any ingredient (such as dimethyl sulfoxide, cyclophosphamide, fludarabine) or structurally similar compounds treated in this trial; 4. Failure to recover from adverse reactions related to previous surgery or treatment to < Grade 2 CTCAEV5.0; 5. Hypertension that remains uncontrolled after combined treatment with 2 drugs or clinically significant (such as active) Cardiovascular and cerebrovascular diseases, such as cerebrovascular accident (within 6 months before signing the informed consent form), myocardial infarction (within 6 months before signing the informed consent form), unstable angina, congestive heart failure classified as class II or above by the New York Heart Association, or severe arrhythmia that cannot be controlled with medication or has a potential impact on study treatment; the electrocardiogram showed obvious abnormality or average QTc interval ≧ 450ms for 3 consecutive times (at least 5 minutes interval); 6. Combined with other serious organic diseases and mental disorders; 7. Suffering from systemic active infections requiring treatment, including but not limited to active tuberculosis, known HIV positive patients or patients with clinically active hepatitis A, B, or C include virus carriers; 8. Have a history of inflammatory bowel disease and autoimmune diseases judged by the researcher to be unsuitable for this study (such as systemic lupus erythematosus, vasculitis, etc.); 9. Those who plan to use the following drugs within 4 weeks before cell therapy and during the study: long-term systemic use steroid hormones, hydroxyurea, immunomodulatory drugs (such as interleukin 2, alpha or gamma interferon, GM-CSF, mTOR inhibitors, cyclosporins, thymosin, etc.); 10. People with brain metastasis: 1. Symptomatic brain metastasis should be ruled out. Patients with a previous history of symptomatic brain metastasis and stable symptoms after local treatment were enrolled in the group who did not need antiepileptic drugs and steroids at least 14 days before lymphocyte clearance. 2. Subjects with asymptomatic brain metastasis without tumor-related brain edema, displacement, steroids or antiepileptic drugs can be enrolled. 3. Subjects with meningitis or meningeal metastasis need to be excluded. 11. People with bleeding or thromboembolism tendency: 1. Have clinically significant bleeding symptoms or obvious bleeding tendency within 2 weeks before the study; 2. Have inherited or acquired bleeding and thrombosis tendencies; 3. A serious arterial/venous thromboembolic event within the past 6 months. 12. Suffering from massive pericardial effusion or symptomatic thoracic or abdominal effusion; 13. Have received live attenuated vaccines within 4 weeks before cell infusion, or plan to receive this type of vaccine during the study; 14. History of organ allogeneic transplantation, allogeneic stem cell transplantation and renal replacement therapy; 15. Uncontrolled diabetes, pulmonary fibrosis, interstitial lung disease, acute lung disease or liver failure; 16. Known alcohol and/or drug abusers; 17. Pregnant or breastfeeding women; 18. Have any coexisting medical conditions or diseases that the researcher determines may impair the conduct of this trial subjects; 19. No legal capacity/restricted capacity; 20. Have previously received any gene or cell therapy products.

Gender: All

Minimum age: 18 Years

Maximum age: 75 Years

Healthy volunteers: No

Locations:

Facility:
Name: Henan Cancer Hospital

Address:
City: Zhengzhou
Zip: 450008
Country: China

Start date: August 1, 2024

Completion date: April 1, 2027

Lead sponsor:
Agency: Henan Cancer Hospital
Agency class: Other

Source: Henan Cancer Hospital

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT06546150